Striving for sustainable growth beyond FY24

17 Jan 2024
5 Min read 
  • Cipla focuses on sustainable growth beyond FY24 with a robust ANDA pipeline.
  •  The company aims to enhance its prescription base and strengthen its generics and consumer healthcare businesses.
  •  Cipla is developing difficult-to-manufacture products in the US generics segment.
  •  Valued at 25x forward earnings, Cipla has a target price of INR1,540.
  •  Cipla is a top pick in the large-cap pharma space due to its growth levers and pipeline.
  •  The text provides cash flow statements and projections, showing inflows, outflows, and closing balances.
Login / Open Demat Account to read the report

Never Miss Out on Hot Market Updates

Get exclusive market news delivered to your inbox - on priority